期刊文献+

接受新辅助治疗患者的麻醉管理进展

Progress in anesthesia management for patients receiving neoadjuvant therapy
原文传递
导出
摘要 新辅助治疗可缩小恶性肿瘤、破坏恶性肿瘤细胞以及降低手术难度。术前接受新辅助治疗已逐渐成为肿瘤患者常见治疗方式之一,其对机体免疫系统、心血管系统、呼吸系统及全身多器官产生重要影响,可能关系到围手术期管理决策。文章就接受新辅助治疗的恶性肿瘤患者的手术时机、术前预康复策略、麻醉管理方式及要点等进行综述,以期为此类患者临床麻醉管理提供一定参考。此外,如何改善接受新辅助治疗患者的预后,确定最佳麻醉方式及药物使用,有待进一步研究。 Neoadjuvant therapy can shorten malignant tumor,destroy malignant tumor cells and reduce surgical difficulties.Preoperative neoadjuvant therapy has become one of the common treatment modalities for patients with malignant tumor,with pivotal effects on the immune system,cardiovascular system,respiratory system,and functions of multiple organs,and is relevant to perioperative management strategies.This review will summarize the perioperative management of patients with neoadjuvant therapy,including timing of surgery,prehabilitation strategies,and anesthesia management strategies,so as to provide reference for improvement in clinical anesthesia management.In addition,further research is needed to improve the prognosis of patients receiving neoadjuvant therapy and to determine the optimal anesthesia practice and medication.
作者 王汇贤 翟蓉 王薇 薄禄龙 Wang Huixian;Zhai Rong;Wang Wei;Bo Lulong(Faculty of Anesthesiology,Changhai Hospital,Naval Medical University,Shanghai 200433,China)
出处 《国际麻醉学与复苏杂志》 CAS 2023年第2期193-197,共5页 International Journal of Anesthesiology and Resuscitation
基金 海军军医大学第一附属医院"234学科攀峰计划"(2020YXK053)。
关键词 肿瘤 新辅助治疗 麻醉 器官功能 围手术期 Tumor Neoadjuvant therapy Anesthesia Organ function Perioperative period
  • 相关文献

参考文献5

二级参考文献13

  • 1邱献华,王海学.新辅助化疗加手术治疗乳腺癌的临床观察[J].现代肿瘤医学,2006,14(9):1071-1073. 被引量:8
  • 2Miln e SE, Troy A, Irwin MG, et al. Relationship between bispectral index, auditory evoked potential index and effect-site EC50 for propofol at two clinical end-points. Br J Anaesth, 2003, 90(2): 127-131.
  • 3Zsigmond EK, Robins G. The effect of a series of anticancer drugs on plasma cholinesterase activity. Can Anaesth Soc J, 1972, 19 (1): 75-82.
  • 4Rajasekhar A, George TJ Jr. Gemcitabine-induced reversible posterior leukoencephalopathy syndrome: a case report and review of the literature. Oncologist, 2007, 12( 11 ) : 1332-1335.
  • 5Martin G, Bellido L, Cruz JJ. Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oneol, 2007, 25 (23): 3559.
  • 6Kastrup O, Diener HC. TNF- antagonist etanercept induced reversible posterior leukoencephalopathy syndrome. J Neurol, 2008, 255(3): 452-453.
  • 7Onujiogu N, Lengyel E, Yamada SD. Reversible posterior leukoencephalopathy syndrome following intravenous paclitaxel and intraperitoneal cisplatin chemotherapy for fallopian tube cancer. Gynecol Oncol, 2008, 111(3): 537-539.
  • 8Vardy J, Wefel J, Ahles T, et al. Cancer and cancer-therapy related cognitive dysfunction: an international perspective from the Venice cognitive workshop. Ann Oncol, 2008, 19(4): 623-629.
  • 9Muldoon LL, Soussain C, Jahnke K, et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol, 2007, 25(16): 2295-2305.
  • 10Rosenow S, Kooistra KL, Powis G, et al. Increased toxicity of the antitumor drug cyclophosphamide in mice in the presence of the volatile anesthetic agent halothane. Cancer Chemother Pharmacol, 1986, 16(1): 3542.

共引文献26

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部